CRXT - Clarus' oral testosterone product Jatenzo gets patent nod

Clarus Therapeutics (NASDAQ:CRXT) said on Wednesday that the U.S. Patent and Trademark Office had issued a new patent for claims that cover its oral testosterone replacement product, Jatenzo. (CRXT) shares rose 5.3% before the bell. The patent will expire in January 2027. Jatenzo is FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions. "We believe that having eight patents listed in FDA’s Orange Book underscores our multi-pronged strategy for success in the marketplace by protecting this important asset," said Clarus' CEO Robert Dudley.

For further details see:

Clarus' oral testosterone product Jatenzo gets patent nod